GlassScriptPhysician profile
Julie R Aull
NPI 1982617387
$5,354.91
in general payments reported to CMS, 2019-2025
31 companies · $683 in 2025
The $683 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $707 · 2022: $1,528 · 2023: $913 · 2024: $1,524 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,972.56 | 2021-2025 | |
| Novo Nordisk INC | $408.60 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $388.18 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $290.26 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $272.05 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $213.02 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.05 | 2022-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $146.81 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceutical Holding Company LTD. | $141.03 | 2022 | |
| Merck Sharp & Dohme LLC | $136.98 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $132.83 | 2021-2024 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $129.73 | 2022-2024 | |
| Exact Sciences Corporation | $118.80 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $107.91 | 2022-2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $107.34 | 2022-2023 | Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $105.80 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $90.60 | 2021 | |
| Antares Pharma, INC. | $61.47 | 2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $58.05 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.05 | 2022-2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $41.33 | 2022-2025 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $37.84 | 2021-2023 | Livalo, Seglentis |
| Axsome Therapeutics, INC. | $35.79 | 2024-2025 | Auvelity |
| Pulmonx Corporation | $22.11 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Agios Pharmaceuticals, INC. | $19.84 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.82 | 2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $18.48 | 2023 | Injectafer |
| Mylan Specialty L.P. | $17.48 | 2024 | Yupelri |
| Lifescan, INC. | $16.90 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.44 | 2024 | Caplyta |
| Esperion Therapeutics, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Aull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.